Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
Antivir Ther
    February 2024
  1. LEPIK KJ, Hunt OL, Bacani N, Wang L, et al
    Adverse drug reactions attributed to generic substitution of antiretroviral medications among HIV treatment and pre-exposure prophylaxis clients in British Columbia, Canada.
    Antivir Ther. 2024;29:13596535241233128.
    >> Share

    December 2023
  2. MARGOT N, Pennetzdorfer N, Naik V, Rhee M, et al
    Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.
    Antivir Ther. 2023;28:13596535231220754.
    >> Share

    June 2023
  3. ARMSTRONG I, Lacombe-Duncan A, Shokoohi M, Persad Y, et al
    Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV.
    Antivir Ther. 2023;28:13596535231182505.
    >> Share

  4. ZILWA N, Mpejane O, Mehboob G, Gill S, et al
    Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report.
    Antivir Ther. 2023;28:13596535231186727.
    >> Share

    February 2023
  5. PETERS E, Iwuji AC
    Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review.
    Antivir Ther. 2023;28:13596535231159030.
    >> Share

  6. ROLLE CP, Castano J, Nguyen V, Patel K, et al
    Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
    Antivir Ther. 2023;28:13596535231163703.
    >> Share

  7. DE WAAL R, Rabie H, Technau KG, Eley B, et al
    Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts.
    Antivir Ther. 2023;28:13596535231168480.
    >> Share

    October 2022
  8. TYAGI A, Tong Y, Rabideau DJ, Reynolds Z, et al
    Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case-control study from Uganda and South Africa.
    Antivir Ther. 2022;27:13596535221114822.
    >> Share

    August 2022
  9. ALVAREZ E, Campbell L, Tinago W, Garcia-Leon A, et al
    The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
    Antivir Ther. 2022;27:13596535221094898.
    >> Share

  10. VAN DER VEER MA, Jacobs TG, Bukkems LH, Colbers AP, et al
    Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report.
    Antivir Ther. 2022;27:13596535221119932.
    >> Share

    June 2022
  11. MUSENGIMANA G, Tuyishime E, Kiromera A, Malamba SS, et al
    Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Antivir Ther. 2022;27:13596535221102690.
    >> Share

  12. EUROPEAN PREGNANCY AND PAEDIAT, Lyons A, Thompson L, Chappell E, et al
    Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.
    Antivir Ther. 2022;27:13596535221092182.
    >> Share

    April 2022
  13. ROEDIGER R, Smyth EK, Dieterich D
    Adefovir for lamivudine-resistant hepatitis B.
    Antivir Ther. 2022;27:13596535211067605.
    >> Share

  14. LEE WA, Cheng AK
    Tenofovir alafenamide fumarate.
    Antivir Ther. 2022;27:13596535211067600.
    >> Share

  15. ABDOOL KARIM SS, Baxter C, Abdool Karim Q
    Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
    Antivir Ther. 2022;27:13596535211067589.
    >> Share

  16. PAN CQ
    The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B.
    Antivir Ther. 2022;27:13596535221076640.
    >> Share

  17. CHOUDHARY MC, Mellors JW
    The transformation of HIV therapy: One pill once a day.
    Antivir Ther. 2022;27:13596535211062396.
    >> Share

  18. SCHINAZI RF, Patel D, Ehteshami M
    The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.
    Antivir Ther. 2022;27:13596535211067599.
    >> Share

  19. YANG T, Oliyai R, Kent KM
    The making of the one pill-Developing single tablet regimens for HIV and for HCV.
    Antivir Ther. 2022;27:13596535211067606.
    >> Share

    November 2021
  20. PRESSIAT C, Dainguy E, Treluyer JM, Yonaba C, et al
    Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus.
    Antivir Ther. 2021;26.
    >> Share

    May 2021
  21. MAGGIOLO F, Gianotti N, Comi L, Di Filippo E, et al
    Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
    Antivir Ther. 2021;26.
    >> Share

  22. SCHEIBE K, Urbanska A, Jakubowski P, Hlebowicz M, et al
    Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Antivir Ther. 2021;26.
    >> Share

    March 2021
  23. DORWARD J, Gbinigie O, Cai T, Roberts NW, et al
    The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.
    Antivir Ther. 2021 Mar 11. doi: 10.3851/IMP3385.
    >> Share

    January 2021
  24. ALEJOS B, Suarez-Garcia I, Bernardino JI, Blanco JR, et al
    Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort.
    Antivir Ther. 2021 Jan 20. doi: 10.3851/IMP3380.
    >> Share

  25. LEE JE, Lee SO, Heo J, Kim DW, et al
    Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
    Antivir Ther. 2021;26.
    >> Share

  26. UGARTE A, De la Mora L, Martinez-Rebollar M, Mallolas J, et al
    An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide-induced cholestasis.
    Antivir Ther. 2021;26.
    >> Share

    November 2020
  27. BRUNET L, Wyatt C, Hsu R, Mounzer K, et al
    Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals.
    Antivir Ther. 2020 Nov 19. doi: 10.3851/IMP3373.
    >> Share

    October 2020
  28. JIA J, Shang J, Tang H, Jiang J, et al
    Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.
    Antivir Ther. 2020 Oct 22. doi: 10.3851/IMP3372.
    >> Share

    August 2020
  29. BEUDEKER BJ, Groothuismink ZM, de Man RA, Janssen H, et al
    Hepatitis B core-related antigen levels predict pegylated interferon-alpha therapy response in HBeAg-positive chronic hepatitis B.
    Antivir Ther. 2020 Aug 3. doi: 10.3851/IMP3367.
    >> Share

    June 2020
  30. SMOLDERS EJ, Te Brake LH, Burger DM
    SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
    Antivir Ther. 2020 Jun 26. doi: 10.3851/IMP3365.
    >> Share

  31. FOCA A, Dhillon A, Lahlali T, Lucifora J, et al
    Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes.
    Antivir Ther. 2020 Jun 4. doi: 10.3851/IMP3361.
    >> Share

  32. XIE X, Jiang Y, Zeng Y, Liu H, et al
    Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.
    Antivir Ther. 2020 Jun 4. doi: 10.3851/IMP3362.
    >> Share

  33. ZHANG Q, Li X, Qiao S, Shen Z, et al
    Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China.
    Antivir Ther. 2020 Jun 1. doi: 10.3851/IMP3360.
    >> Share

    May 2020
  34. TOKA B, Koksal AS, Iskender G, Cakmak E, et al
    HBV flare associated with immunosuppressive treatments: it is still dangerous in the third-generation antivirals era.
    Antivir Ther. 2020 May 4. doi: 10.3851/IMP3356.
    >> Share

    April 2020
  35. BLACKMAN AL, Heil EL, Devanathan AS, Pandit NS, et al
    The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
    Antivir Ther. 2020 Apr 28. doi: 10.3851/IMP3355.
    >> Share

  36. HOFFMANN C, Schewe K, Fenske S, Buhk T, et al
    Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
    Antivir Ther. 2020 Apr 1. doi: 10.3851/IMP3351.
    >> Share

    March 2020
  37. ARENAS-PINTO A, Stohr W, Khoo S, Clarke A, et al
    Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.
    Antivir Ther. 2020 Mar 23. doi: 10.3851/IMP3340.
    >> Share

    February 2020
  38. BARANEK B, Wang S, Cheung AM, Mishra S, et al
    The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.
    Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.
    >> Share

  39. DENG H, Liang S, Xu M, Zhuo L, et al
    Clinical efficacy and safety in telbivudine- or tenofovir-treated hepatitis B e antigen-positive pregnant women.
    Antivir Ther. 2020 Feb 12. doi: 10.3851/IMP3345.
    >> Share

    January 2020
  40. MAJEED SR, West S, Ling KH, Das M, et al
    Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
    Antivir Ther. 2020 Jan 14. doi: 10.3851/IMP3343.
    >> Share

    December 2019
  41. BIERHOFF M, Smolders EJ, Tarning J, Burger DM, et al
    Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review.
    Antivir Ther. 2019 Dec 23. doi: 10.3851/IMP3341.
    >> Share

  42. ABREU RM, Bassit LC, Tao S, Jiang Y, et al
    Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.
    Antivir Ther. 2019 Dec 4. doi: 10.3851/IMP3338.
    >> Share

    September 2019
  43. AKANBI OA, Harms D, Wang B, Osundare FA, et al
    High frequency of drug resistance mutations in the HBV genome in ART-experienced HIV-coinfected patients in southwestern Nigeria.
    Antivir Ther. 2019 Sep 30. doi: 10.3851/IMP3333.
    >> Share

    April 2019
  44. BOERMA R, Schellekens O, Rinke de Wit TF, Wit FW, et al
    Reaching 90-90-90: outcomes of a 15-year multi-country HIV workplace programme in sub-Saharan Africa.
    Antivir Ther. 2019 Apr 24. doi: 10.3851/IMP3311.
    >> Share

  45. HUDSON FP, Mulenga L, Westfall AO, Warrier R, et al
    Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka Zambia.
    Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3299.
    >> Share

  46. ARMENIA D, Di Carlo D, Lepri AC, Calcagno A, et al
    Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
    Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3309.
    >> Share

    February 2019
  47. HUNT GM, Ledwaba J, Kalimashe M, Salimo A, et al
    Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods.
    Antivir Ther. 2019 Feb 11. doi: 10.3851/IMP3294.
    >> Share

    January 2019
  48. HALLORAN MO, Boyle C, Kehoe B, Bagkeris E, et al
    Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.
    Antivir Ther. 2019 Jan 31. doi: 10.3851/IMP3293.
    >> Share

  49. HANHOFF N, Vu Q, Lang R, Gill MJ, et al
    Impact of three decades of antiretroviral therapy in a longitudinal population cohort study.
    Antivir Ther. 2019 Jan 7. doi: 10.3851/IMP3287.
    >> Share

    September 2018
  50. LADAK F, Socias E, Nolan S, Dong H, et al
    Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Antivir Ther. 2018 Sep 19. doi: 10.3851/IMP3265.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016